These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24129412)

  • 1. Real-time in vivo imaging of invasive- and biomaterial-associated bacterial infections using fluorescently labelled vancomycin.
    van Oosten M; Schäfer T; Gazendam JA; Ohlsen K; Tsompanidou E; de Goffau MC; Harmsen HJ; Crane LM; Lim E; Francis KP; Cheung L; Olive M; Ntziachristos V; van Dijl JM; van Dam GM
    Nat Commun; 2013; 4():2584. PubMed ID: 24129412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyomyositis as a nontropical disease.
    Harbarth SJ; Lew DP
    Curr Clin Top Infect Dis; 1997; 17():37-50. PubMed ID: 9189660
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual Fluorescent- and Isotopic-Labelled Self-Assembling Vancomycin for in vivo Imaging of Bacterial Infections.
    Yang C; Ren C; Zhou J; Liu J; Zhang Y; Huang F; Ding D; Xu B; Liu J
    Angew Chem Int Ed Engl; 2017 Feb; 56(9):2356-2360. PubMed ID: 28124815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two fluorescent probes in preclinical non-invasive imaging and image-guided debridement surgery of Staphylococcal biofilm implant infections.
    Park HY; Zoller SD; Hegde V; Sheppard W; Burke Z; Blumstein G; Hamad C; Sprague M; Hoang J; Smith R; Romero Pastrana F; Czupryna J; Miller LS; López-Álvarez M; Bispo M; van Oosten M; van Dijl JM; Francis KP; Bernthal NM
    Sci Rep; 2021 Jan; 11(1):1622. PubMed ID: 33452271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential for bio-optical imaging of biomaterial-associated infection in vivo.
    Sjollema J; Sharma PK; Dijkstra RJ; van Dam GM; van der Mei HC; Engelsman AF; Busscher HJ
    Biomaterials; 2010 Mar; 31(8):1984-95. PubMed ID: 19969345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
    Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
    Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
    Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A light-up probe with aggregation-induced emission characteristics (AIE) for selective imaging, naked-eye detection and photodynamic killing of Gram-positive bacteria.
    Feng G; Yuan Y; Fang H; Zhang R; Xing B; Zhang G; Zhang D; Liu B
    Chem Commun (Camb); 2015 Aug; 51(62):12490-3. PubMed ID: 26149530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
    Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
    Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics.
    Chua K; Howden BP
    Curr Opin Infect Dis; 2009 Dec; 22(6):525-34. PubMed ID: 19738465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteria-targeted fluorescence imaging of extracted osteosynthesis devices for rapid visualization of fracture-related infections.
    López-Álvarez M; Heuker M; Sjollema KA; van Dam GM; van Dijl JM; IJpma FFA; van Oosten M
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2276-2289. PubMed ID: 35079847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro evaluation, and in vivo metabolism of fluor/quencher compounds containing IRDye 800CW and Black Hole Quencher-3 (BHQ-3).
    Linder KE; Metcalfe E; Nanjappan P; Arunachalam T; Ramos K; Skedzielewski TM; Marinelli ER; Tweedle MF; Nunn AD; Swenson RE
    Bioconjug Chem; 2011 Jul; 22(7):1287-97. PubMed ID: 21639144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsically vancomycin-resistant gram-positive organisms: clinical relevance and implications for infection control.
    Nelson RR
    J Hosp Infect; 1999 Aug; 42(4):275-82. PubMed ID: 10467540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
    Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.